Original Source(s)
Related Content
FDA clears targeted cholangiocarcinoma therapy
In the single-arm REFOCUS trial, 46% of patients responded to treatment, with a median response duration of 11.8 months.
September 24, 2026
-
2 min
Trends in alcohol-linked cancer mortality
Investigators examined 3 decades of US cancer mortality estimates across age, sex, region, and cancer type.
September 28, 2026
-
3 min
10 Growing US Metro Areas to Consider for Private Practice
These 10 metropolitan areas recorded population growth and had recently completed, ongoing, or announced health care infrastructure projects.
September 1, 2026
-
5 min
